Expert panelists provide an overview of adverse events associated with bispecific antibodies for the treatment of multiple myeloma along with best practices for monitoring and treating adverse events.
This is a video synopsis/summary of a Practice Pearls involving Ryan Haumschild, PharmD, MS, MBA; Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.
Perissinotti reviews key adverse events of concern with bispecific antibodies for relapsed/refractory multiple myeloma: cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS) and infections. He explains CRS pathophysiology, clinical grading system, and typical interventions like steroids/tocilizumab for grade 2 or higher CRS. ICANS manifestations are delirium and motor deficits assessed by a standard Immune Effector Cell–Associated Encephalopathyscoring system; steroids are first-line treatment. Finally, Perissinotti notes unique toxicities with talquetamab including skin/eye issues and dysgeusia.
Haumschild highlights the importance of pharmacists helping manage adverse effects through grading; order set optimization enabling consistent, standardized responses; and recognizing unique toxicity profiles. He notes variability across centers in prophylactic approaches, making consensus grading systems valuable. Central roles are also educating patients on expected adverse effects and optimizing supportive care.
Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.